Stockscreener 앱 받기
3.38
12.29%
0.37
시간 외 거래:
3.38
Opus Genetics Inc 주식(IRD)의 최신 뉴스
Revenues Not Telling The Story For Opus Genetics, Inc. (NASDAQ:IRD) After Shares Rise 43% - simplywall.st
Aug Opening: Is Opus Genetics Inc a strong growth stock2025 Price Targets & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Opus Genetics, Inc. (NASDAQ:IRD) Short Interest Update - MarketBeat
Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026 - GlobeNewswire
Why Opus Genetics Inc. (R3X1) stock could rally stronglyJuly 2025 Rallies & Weekly High Momentum Picks - mfd.ru
Opus Genetics' (IRD) "Buy" Rating Reiterated at BTIG Research - MarketBeat
Where Opus Genetics Stands With Analysts - Benzinga
Opus Genetics to begin MERTK gene therapy trial in Abu Dhabi - Investing.com India
Opus Genetics (IRD) Initiates Gene Therapy Trial for Eye Disorder - GuruFocus
Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa - The Manila Times
Fundamentals Check: Is TrueCar Inc. a stock for growth or value investorsExit Point & Low Volatility Stock Recommendations - baoquankhu1.vn
Opus Genetics, Inc. (NASDAQ:IRD) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Opus Genetics, Inc. (NASDAQ:IRD) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Take Profit: Is Opus Genetics Inc benefiting from innovation trendsJuly 2025 Outlook & AI Powered Market Trend Analysis - baoquankhu1.vn
BTIG Research Begins Coverage on Opus Genetics (NASDAQ:IRD) - Defense World
Opus Genetics (NASDAQ:IRD) Stock Rating Upgraded by BTIG Research - MarketBeat
BTIG Initiates Coverage of Opus Genetics (IRD) with Buy Recommendation - Nasdaq
Opus Genetics stock initiated with Buy rating at BTIG on retinal disease focus - Investing.com Canada
BTIG Initiates Coverage on Opus Genetics (IRD) with a Buy Rating - GuruFocus
Wall Street Zen Upgrades Opus Genetics (NASDAQ:IRD) to Hold - MarketBeat
JPM26: Opus Genetics builds momentum in rare retinal gene therapy - Yahoo Finance
Opus Genetics, Inc. Announces Presentation at J.P. Morgan Healthcare Conference - TradingView
Virtual Reality Endpoints Improve Measurement Of Patients' Real-World Benefit - Clinical Leader
Opus Genetics highlights 2025 progress, upcoming 2026 catalysts - Yahoo Finance
How Opus Genetics Inc. stock reacts to oil pricesWeekly Profit Report & Risk Controlled Daily Trade Plans - Улправда
Merger Talk: How cyclical is Opus Genetics Inc. (R3X1) stock compared to rivalsTrade Risk Summary & Free Accurate Trade Setup Notifications - Улправда
How cyclical is Opus Genetics Inc. (R3X1) stock compared to rivals2025 Momentum Check & Community Verified Watchlist Alerts - Улправда
Earnings Risk: Is Opus Genetics Inc. stock attractive for growth ETFsPortfolio Performance Summary & Free Community Supported Trade Ideas - Улправда
How interest rate cuts could boost Opus Genetics Inc. stock2025 Major Catalysts & Weekly Stock Performance Updates - Улправда
Opus Genetics (IRD) Advances Clinical Trials and Regulatory Fili - GuruFocus
Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts - The Manila Times
Opus Genetics Details 2025 Progress and 2026 Milestones - TipRanks
Opus Genetics Highlights 2025 Progress and 2026 Catalysts - TradingView — Track All Markets
Opus Genetics (NASDAQ:IRD) Cut to Sell at Wall Street Zen - Defense World
Independent Chairman of Opus Genetics Picks Up 9.5% More Stock - simplywall.st
Caprolactam Chemicals Limited Stock Analysis Technical Signals for YEAR - earlytimes.in
What drives Opus Genetics Inc stock priceEx-Dividend Date Alerts & Small Investment Portfolio - earlytimes.in
Hedge Fund and Insider Trading News: Ken Griffin, Warren Buffett, Bridgewater Associates, AQR Capital Management, Schonfeld Strategic Advisors, D.E. Shaw, Millennium Management, Elliott Management, Discovery Capital Management, Opus Genetics Inc - Insider Monkey
Opus Genetics Advances Gene Therapy for Retinal Degeneration: A Study Update - MSN
Portfolio Shifts: How Opus Genetics Inc stock performs in stagflationWeekly Market Outlook & Low Risk High Reward Trade Ideas - moha.gov.vn
Opus Genetics (NASDAQ:IRD) Director Cam Gallagher Purchases 83,000 Shares - MarketBeat
Shorts Report: Why Opus Genetics Inc R3X1 stock is upgraded to buy - moha.gov.vn
B Riley Securities initiates coverage of Opus Genetics (IRD) with buy recommendation - MSN
Opus Genetics, Inc. (NASDAQ:IRD) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Soaring Eagle Acquisition Corp Equity Warrant Stock Analysis and ForecastLong-Term Growth Stocks & Superior Capital Appreciation - earlytimes.in
Opus Genetics Inc R3X1 Stock Analysis and ForecastMarket Insider Reports & Discover Strategies with Fellow Traders - earlytimes.in
MACD Signals Flash Warning for Compucom Software Limited StockMACD Trading Signals & Minimal Investment Big Returns - earlytimes.in
Opus Genetics rises as eye disease study to proceed without changes - MSN
Rate Hike: Why Opus Genetics Inc stock could benefit from AI revolutionInsider Selling & Proven Capital Preservation Tips - moha.gov.vn
Will Opus Genetics Inc. stock outperform growth indexesProfit Target & Consistent Growth Equity Picks - Улправда
Palmetto Grain Brokerage - Palmetto Grain Brokerage
Will Opus Genetics Inc. stock gain from lower inflationMarket Growth Summary & Low Risk Profit Maximizing Plans - Улправда
0.10%
7.16%
자본화:
|
볼륨(24시간):